key: cord-0935374-39eghguo
authors: Guarneri, Valentina; Bassan, Franco; Zagonel, Vittorina; Milella, Michele; Zaninelli, Marta; Cattelan, Anna Maria; Vianello, Andrea; Gori, Stefania; Aprile, Giuseppe; Azzarello, Giuseppe; Chiari, Rita; Favaretto, Adolfo; Oliani, Cristina; Scola, Annamaria; Pastorelli, Davide; Mandarà, Marta; Zustovich, Fable; Bernardi, Daniele; Chiarion-Sileni, Vanna; Morandi, Paolo; Toso, Silvia; Di Liso, Elisabetta; Ziampiri, Stamatia; Caccese, Mario; Zampiva, Ilaria; Puccetti, Oliviero; Celestino, Michele; Dieci, Maria Vittoria; Conte, PierFranco
title: Epidemiology and clinical course of SARS-CoV-2 infection in cancer patients in the Veneto Oncology Network: The ROVID Study
date: 2021-02-03
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2021.01.021
sha: 7772d9b177ef1f3360a41e57dd995aa0dce70563
doc_id: 935374
cord_uid: 39eghguo

INTRODUCTION: COVID-19 pandemic started in Italy with clusters identified in Northern Italy. The Veneto Oncology Network ROV licensed dedicated guidelines to ensure proper care minimizing the risk of infection in cancer patient. ROVID is a regional registry aimed at describing epidemiology and clinical course of SARS-CoV-2 infection in cancer patients. MATERIALS AND METHODS: Patients with cancer diagnosis and documented SARS-CoV-2 infection are eligible. Data on cancer diagnosis, comorbidities, anticancer treatments as well as details on SARS-CoV-infection (hospitalization, treatments, fate of the infection) have been recorded. Logistic regression analysis was applied to calculate the association between clinical/laboratory variables and death from any cause. RESULTS: 170 patients have been enrolled. Median age at time of the SARS-CoV-infection was 70 years (25-92). The most common cancer type was breast cancer (n=40). The majority of the patients had stage IV disease. Half of the patients had 2 or more comorbidities. The majority of the patients (78%) presented with COVID-19 symptoms. More than 77% of the patients were hospitalized, and 6% were admitted to intensive care units. Overall, 104 patients have documented resolution of the infection. Fifty-seven patients (33%) have died. In 29 cases (17%) the cause of death was directly correlated to SARS-CoV-2 infection. Factors significantly correlated with the risk of death were: ECOG PS, age, presence of 2 or more comorbidities, presence of dyspnea, COVID-19 phenotype >=3, hospitalization, intensive care unit admission, neutrophils/lymphocytes ratio and thrombocytopenia. CONCLUSIONS: The mortality rate reported in this confirms the frailty of this population. These data reinforce the need to protect cancer patients from SARS-CoV2 infection.

On February 21, 2020, in the Veneto region occurred the country's first death from coronavirus 19 disease . In early March 2020, the rapid global spread of the SARS-CoV-2 infection led World Health Organization (WHO) to declare a pandemic. 1 Since the beginning of COVID-19 outbreak, the Veneto region started a proactive approach, including testing for SARS-CoV-2 the asymptomatic population living in area of the initial outbreak as well as healthcare providers. 2 To face the emergency of the first weeks, the national health system was reorganized to implement wards dedicated to COVID-19 patients and to potentiate intensive care units. In this context, maintaining oncology care was considered one of the priority of the regional health system. To ensure proper cancer care minimizing the risk of infection, the Veneto Oncology Network (Rete Oncologica Veneta -ROV) licensed a dedicated diagnostictherapeutic pathway (PDTA), a workflow harmonizing protective measures for oncologic patients and staff members across the 26 Medical Oncology Units operating in the Veneto region. 3 Indeed, it was immediately clear since the very beginning of the pandemic, that cancer patients with SARS-Cov-2 infection might be at higher risk of developing severe complications and death. 4 Patients with cancer are usually susceptible to infectious disease, and infections are a leading cause of death among this patient population. This vulnerability is related to the immunosuppressive state caused by underlying malignancy and anticancer treatments, and also to comorbidities. Starting from the first retrospective cohort in China, describing a higher risk of severe events for cancer versus non-cancer patients, data from several multicentric registries including hundreds of cancer patients reported a mortality rate in the range of 10-33%. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] It is important to note, however, the huge heterogeneity of the clinical course of SARS-CoV-2 infection across different countries. Mortality, the most important measure of COVID-19 disease burden, largely differs across countries. As of December 2020, the case fatality ratio ranges from to 0.2% J o u r n a l P r e -p r o o f to 9.7%. In Europe, Italy reaches one of the highest case fatality ratio (3.5%). 18 Differences in demographics, availability of personal protective equipment, testing strategy and characteristics of healthcare systems might account for this variability in mortality. In this framework, a regional registry (ROVID) has been set up with the aim of describing epidemiology and clinical course of SARS-CoV-2 infection in cancer patients treated following shared guidelines and in services relying on the same resources.

The ROVID study is an observational study including patients with cancer diagnosis and documented SARS-CoV-2 infection (positive nasopharyngeal swab University Hospital, which is Regional Reference Laboratory for emerging viral infections and received accreditation as Reference Laboratory for SARS-CoV-2 testing. With the growing of the pandemic, other laboratories using the same methodology were subsequently certified by the regional government.

According to The Italian Society of Emergency and Urgency Medicine recommendations, patients have been classified in 5 COVID-19 phenotypes: type 1: presence of fever, no hypoxaemia at arterial Blood Gas Analysis (BGA), normal chest radiograph; type 2: fever and pulmonary consolidation area at chest radiograph, or mild hypoxia at BGA; type 3: fever associate to moderate-severe respiratory insufficiency and bilateral pulmonary consolidation area at Chest XR; type 4: preARDS (Adult Respiratory Distress Syndrome) requiring mechanical ventilation; type 5: subjects with ARDS. 19 The complete set of variables is listed in supplemental appendix 1. The data extracted from electronical medical records are entered into a de-identified REDCap (Research Electronic Data Capture) database. Each participating institution is assigned a unique number, and access to the database is password protected. To study the association between clinical/laboratory variables and outcome (death from any cause), odds ratios (ORs) and their 95% confidence intervals (95% CIs) were calculated by logistic regression analysis. Statistical analyses were performed by using IBM® SPSS® Statistics (version 26). The protocol was approved by Institutional review board of participating centers. All study procedures were in accordance with the precepts of good Clinical practice and the declaration of Helsinki. The most frequently reported symptoms were fever (66%), dyspnea (43,5%), cough (38%) (table 2) . Among symptomatic patients, the distribution of clinical phenotype was as follows: type 1: 25%, type 2: 36%, type 3: 24%, type 4: 12 %, type 5: 3%.

More than 77% of the patients were hospitalized, and 6% were admitted to Intensive care In Italy, on April 4 2020, which represent the peak of hospitalization due to COVID 19 during the first wave of the pandemic, patients hospitalized in intensive care units represented 4.4% of the total positive cases. 22 The referral of critically ill cancer patients to intensive care units is often challenging and requires a case by case evaluation weighting the benefit of treating a potentially reversible condition against a futile care. It is therefore important to highlight that in these circumstances cancer patients were offered the same opportunities as compared to non-cancer patients.

We report a median time to negativity of nasopharyngeal swab of 23 days. Our results are in line with those reported in a study conducted in more than 530000 inhabitants in the northeastern Italian province of Udine. In the 974 subjects diagnosed with SARS-CoV-2 infection, the median time to negativity was 23.3 days. 23 Therefore, the kinetic of virus clearance is not negatively affected in cancer patients.

In our study, the overall mortality rate is of 33%, with COVID-19 as primary cause of death in 17% of the cases. We identified several factors significantly correlated with the risk of death. As reported in the vast majority of studies, we confirmed the association of age and comorbidities with an increased risk of death. 14, 16, 24 Poor PS was also associated with an increased risk of death. The association of PS >=2 with increased risk of death has been already described by the CCC19 cohort study including 928 patients, by the French nationwide cohort study (GCO-002 CACOVID-19) including 1289 patients, and by the Gustave Roussy cohort of 178 patients. 6, 9, 16 In our study, presence of dyspnea, COVID-19 phenotype >=3, hospitalization, and intensive care unit admission were all significant predictors of increased risk of death.

Because of the relatively limited sample size, we did not perform a multivariate analysis.

However, it is important to highlight that patients suffering from symptoms are those more likely to experience a fatal outcome. In particular, the presence of dyspnea has been confirmed as predictor of a fatal outcome also in the TERAVOLT study, which included only patients with thoracic malignancies, and in the UKCCMP study. 7, 8 Interestingly, we describe a significant association of neutrophils/lymphocytes ratio and thrombocytopenia with the risk of death. These are simple and easily reproducible tests that might be helpful for an early identification of patients at higher risk for an adverse outcome.

Conflicting data on the association between chemotherapy use and increased risk of death have been reported so far. With the growing of the pandemic, the majority of International Societies made recommendations on the basis of the general principle of the risk-tobenefit ratio, recognizing the need to protect a vulnerable population from a potentially fatal infection, alongside with the potential harms of delaying diagnostic procedures and treatments in cancer patients. 25-28 Therefore, data on the impact of anticancer treatments on the COVID trajectory are largely awaited. The UKCCMP and the CCC19 cohort found no association of increased mortality with recent chemotherapy administration. A recent study from Memorial Sloan Kettering Cancer Center including more than 300 patients found no association between chemotherapy use and adverse COVID19 outcome. 5 In an observational study of 890 European patients with cancer, chemotherapy use was not associated with increased mortality. 14 Interestingly, provision of active anticancer therapy was found to be protective. In the French GCO-002 CACOVID 19, none of the anticancer treatment administered within the previous three months significantly affect mortality or COVID 19 severity. 16 In our ROVID study, we found no association between chemotherapy use and increased risk of death. On the other hand, in the TERAVOLT study, chemotherapy use was associated with an increased risk of death. 8 More recent data from the Gustave Roussy cohort described a significant association between chemotherapy use in the past 3 months and clinical worsening and death. 9 A recent meta-analysis including 16 studies concluded for an increased risk of death for chemotherapy administered within the last 30 days before COVID-19 diagnosis. 29 

It is important to note, however, that all these studies vary in design, endpoints, statistical methods, patients composition, so comparisons are challenging. In our study, active anticancer treatments were discontinued due to SARS-Cov-2 infection diagnosis in two third of the patients. Notably, a decrease in cancer diagnosis and access to cancer facilities have been reported, and some screening services have been temporarily interrupted, raising the concern on a potential increase in cancer mortality overtime due to underdiagnoses or under treatment. 30, 31 In our view, the high mortality rate reported in our and other studies largely overcome these concerns, and in the absence of an effective vaccine and treatment, preventing transmission of SARS-CoV-2 remains the goal. Cancer patients are a fragile population, and maximum effort should be made to ensure proper care in a safe environment. 32 In the ROVID study, disease stage as well as disease setting (curative vs palliative), were not associated with the risk of death, reinforcing the importance of maintaining protective measures for all these patients. Prescreening for symptoms before access to cancer care facilities, the use of telemedicine for follow up visits, where possible prescribing oral drugs can be helpful to protect this vulnerable population.

At time of this report, we are at the beginning of the second wave of the pandemic, with an extremely rapid spread of the contagion worldwide. We acknowledge the limited sample size of this study, as well as the heterogeneity of the population in terms of cancer diagnosis, disease stage, anticancer treatments. However, these data are generated starting from an homogeneous environment in terms of healthcare resources, with shared guidelines for cancer patients treatment during the pandemic discussed and licensed since the beginning. 3 Our data contribute to the knowledge of the trajectory of the disease course in cancer patients, and can helpful for proper cancer care planning at regional and national level. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper 

WHO Director-General's opening remarks at the media briefing on COVID-19-11

Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'

Cancer patients in Sars-Cov-2 infection: a nationwide analysis in China

Chemotherapy and COVID-19 outcomes in patients with cancer

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

Do Patients with Cancer Have a Poorer Prognosis of COVID-19? An Experience in New York City

High mortality rate in cancer patients with symptoms of COVID-19 with or withourt detectable SARS-CoV-2 on RT-PCR

High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study

Dutch Oncology COVID-19 consortium: outcome of COVID-19 in patients with cancer in a nationwide cohort study

Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-10. A nationwide, population-based analysis

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study

Mortality in patients with cancer and coronavirus disease 2019: a systematic review and meta-analysis of 52 studies

DGPREP

SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer

A. detection of severe acure respiratory sindrom coronavirus 2 in nasoparynx according to clinical phenotype of affected patients

The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper

The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region

Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic Breast

Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective. ESMO Open

A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-10

How COVID-19 pandemic impacted integrated care pathways for lung cancer: the experience of two Italian centers in Veneto region

Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic

Cancer and COVID-19: what do we really know?

Acknowledgments: Anna Roma, Medical Oncology 3, Istituto Oncologico Veneto IRCCS,